The fuel cell leader reported full-year 2018 earnings.
The early-stage biotech jumped without any significant news.
The liquid biopsy pioneer has been riding a wave of favorable news lately.
The biosimilar leader announced preliminary sales data for its most important product.
The company announced the pricing of a stock offering. Despite the dilution, it's a well-timed move by management.
Above-average yields can supercharge your portfolio's returns, especially if the dividends or distributions are dished out by solid businesses.
On paper, hydrogen fuels are the ultimate clean energy source. In reality, things are a little more complicated.
Iowa and Nebraska, the two states hit hardest by recent flooding, are home to 40% of the country's ethanol production capacity.
These two businesses operate in important industries that are just beginning periods of exponential growth.
The small-cap pharma announced positive results from a phase 3 trial.
A frack sand supplier and a water technology leader are attractively valued relative to their growth potential.
Most biotech drugs focus on clearing plaques from brain cells, but restoring patients' sleep quality is also proving to be necessary.
Shares have nearly doubled in March following a string of updates, although there was no news on Monday.
Repligen has grown product revenue 220% since 2014, but it trades at 70 times future earnings. What should investors make of that?
American regulators rejected a type 1 diabetes treatment that analysts predicted would eventually eclipse $450 million in annual revenue.
The company reported poor operating performance in 2018, but has attempted to focus the attention of investors on its future.
Wind and solar power will continue to elbow their way onto the electric grid this year, but that's just the beginning.
A leading player in the solar energy industry and a fertilizer company with a twist are two affordable stocks worth a closer look.
This business has a cozy relationship with one of the country's largest ethanol producers, allowing it to pay a 12% distribution yield.
Brazil's oil major has clawed its way back to a $100 billion market cap. Should individual investors be as confident as Wall Street?